Nox Medical Introduces Nox A1s™ PSG System to Product Portfolio


Nox Medical has released the Nox A1s™ PSG system which features hospital-to-home flexibility and product enhancements to its predecessor, Nox A1. The Nox A1s is a future-proof investment with telehealth capabilities to perform in-lab and at-home sleep testing, making it one of the most versatile devices on the market.

“We’re living in a global epidemic of sleeplessness and are committed to being a part of the solution,” said Pétur Már Halldórsson, CEO of Nox Medical. “Our growing product portfolio enables a seamless continuum of care by leveraging telemedicine and innovative technology to address the growing demand for better sleep solutions. We’ve reached the next milestone in our product vision with the launch of the Nox A1s, a true hospital-to-home diagnostic device with revolutionary versatility.”

Like all Nox Medical devices, the Nox A1s was thoughtfully designed with patient comfort, clinical accuracy and increased efficiency in the forefront, allowing sleep professionals to facilitate scalable clinical pathways and help more people achieve better sleep.

In recent studies, Nox A1s has demonstrated low failure rates and reliable, high-quality signals both in Type I in-lab and Type II home unattended settings. 

“The system provides an untethered setup and features bedside control through the Noxturnal App to perform bio-calibration, review signal quality, conduct impedance checks and view live traces — ultimately two huge differentiating factors among other PSG devices on the market,” said Ingvar Hjalmarsson, Chief Product Officer of Nox Medical. 

Nox A1s can be configured through cloud connectivity with Nox Self-Applied Somnography (Nox SAS), allowing patients the revolutionary ability to self-apply the device in the comfort of their own home. The Nox SAS has been used in more than 6,000 sleep studies worldwide, but is currently only available for research purposes.

The Nox A1 first launched in Europe in 2014 and has since earned a reputation as a versatile, cost-effective testing and diagnostic solution that delivers a positive experience for both patients and providers. In June 2021, Nox Medical introduced the Nox A1s to its sales network and distributors before officially launching to the market on October 8, 2021.

The availability of the Nox A1s may vary between markets. Please contact a local distributor or U.S. and Canada sales representative for further information here

Topic: Company Updates